2 Top Stocks I Wouldn’t Hesitate to Invest $1,000 in Right Now

Is it advisable to put money into stocks at present? Some individuals may hold back due to the fluctuations experienced in the broader stock market this year. However, others recognize that the stock market tends to yield substantial profits over a prolonged period, despite any short-term unpredictability.

I’m solidly part of the group that advocates for long-term investments. The strategy is to put money into businesses expected to bring substantial financial success and profits over a period of five years or beyond.

If you, too, are on the hunt for solid investment opportunities, why not give a glance at these two promising companies? They are Shopify (SHOP) and Axsome Therapeutics (AXSM), whose future outlook seems quite strong.

Here’s why I’d invest $1,000 in either of these companies right now.

1. Shopify

Since its initial public offering in 2015, Shopify has surpassed the overall market performance, indicating a promising future with significant growth opportunities remaining for the stocks. As such, given its current level, Shopify represents a solid investment choice.

Ponder over the various factors that make Shopify’s future outlook promising for a prolonged period.

Shopify stands out in the e-commerce sector, serving as a trailblazer for many online retailers. Rather than relying solely on its early entry into the market, it sets itself apart by providing a comprehensive toolkit to its clients. These tools cover various aspects of running an online business such as payment processing, marketing strategies, and data analysis. Additionally, Shopify enables its users to sell products seamlessly across popular social media channels. Furthermore, the platform offers an app store for merchants to tailor their storefronts according to their preferences.

Shopify gains an advantage over others due to factors like the costs associated with switching from its platform and the network effect of its app store. These strengths should keep it as a dominant player in its sector for quite some time. Currently, Shopify holds over 12% share in the U.S. e-commerce market, based on gross merchandise volume.

Thirdly, there’s a significant potential for expansion in the field of e-commerce. As we stand now, just over 16% of retail sales in the United States occur online during the first quarter. Interestingly, Shopify, a platform that operates globally, is active in more than 175 countries, most of which have lower rates of e-commerce than the U.S., indicating a vast array of opportunities ahead.

It’s important to acknowledge that critics may argue that Shopify will encounter tough competition and continue to operate at a loss. However, these obstacles, in my opinion, do not significantly impact Shopify’s overall potential. The company has demonstrated resilience in the face of competition for several years now, and it has even expanded its market share in recent times, growing from 10% as of the end of 2023. Although there are still losses to be addressed, Shopify’s vast opportunities for growth, coupled with recent strategic moves such as divesting its low-margin logistics business, could make it profitable within a short period.

In simpler terms, purchasing Shopify stock is still a good decision. If you invest $1,000, you would end up owning approximately seven shares, and you’d have some money left over.

2. Axsome Therapeutics

Over the past three years, Axsome Therapeutics, a prominent biotechnology company in the mid-tier category, has experienced consistent growth due to impressive advancements in their clinical trials and regulatory approvals.

The company’s present selection of authorized medications comprises Auvelity, used for major depressive disorder (MDD); Symbravo, designed for acute migraines; and Sunosi, prescribed for daytime sleepiness that exceeds normal limits due to sleep apnea or narcolepsy. Axsome obtained Sunosi from Jazz Pharmaceuticals in 2022.

Over the past few years, Axsome Therapeutics’ stock has shown strong performance, largely due to advancements with Auvelity. What makes this even more exciting is that there are significant catalysts ahead for the company. In fact, they plan to file regulatory applications for AXS-12, a potential cataplexy treatment for narcolepsy patients, by the end of this year. Additionally, following Auvelity’s successful phase 3 results in Alzheimer’s disease agitation, Axsome is aiming to expand its label in that area. They anticipate submitting a regulatory application for this during the third quarter.

Excitedly speaking, the latest phase 3 findings on solriamfetol – known as Sunosi generically – in ADHD have broadened possibilities for this medication’s label! What’s more, the same company intends to kick off late-stage studies for MDD later this year, which is truly thrilling.

Currently, Axsome is facing some challenges. Not long ago, the U.S. Food and Drug Administration turned down their application for AXS-14 as a potential treatment for fibromyalgia. The FDA contended that one of the studies provided by Axsome to support approval was insufficient. In response, Axsome intends to conduct another clinical trial in the last quarter of this year to resolve this issue.

For smaller biotech firms like Axsome Therapeutics, experiencing regulatory hurdles during product launches, such as the ones faced with Auvelity and Symbravo, isn’t an unusual event. However, despite these setbacks, Axsome has managed to bring both products to market successfully. Remarkably, it has shown resilience in recent times, thriving even amidst these challenges.

This biotech company continues to be a compelling investment choice, as its array of approved products promises robust revenue expansion in the near term, and its advanced-stage pipeline could enhance its financial performance.

It’s still possible to invest in Axsome Therapeutics, a biotech company that is quickly growing its prominence. For about a thousand dollars, you could buy nine shares of their stock.

2025-07-24 13:29

1. Shopify

2. Axsome Therapeutics

Read More